US FDA approves cheaper saliva test, SalivaDirect for faster Coronavirus detection


Deprecated: strlen(): Passing null to parameter #1 ($string) of type string is deprecated in /home/medicircle/public_html/script_newsdetails.php on line 75
▴ us-fda-approves-cheaper-saliva-test-salivadirect-detecting-covid
SalivaDirect the new saliva based Coronavirus test gets US approval

The US health watchdog has authorised the emergency use of a new and less expensive saliva-based laboratory diagnostic test for COVID-19 that could be a game-changer in the diagnosis of the infection as it will enable rapid testing amongst more people easily.

Stephen Hahn, the Food and Drugs Administration Commissioner, said the new saliva test would increase efficiency and avoid shortage of crucial test components like reagents."Providing this type of flexibility for processing saliva samples to test for COVID-19 infection is groundbreaking in terms of efficiency and avoiding shortages of crucial test components like reagents," he said in a statement.

The agency has previously authorised four other tests that use saliva for sampling, but these yielded varying results. Authorisation of the new test occurs amid ongoing disarray over COVID-19 testing.

The US has been plagued by an inconsistent strategy for detecting the virus, thanks in part to persistent shortages and the use of a variety of different tests that have sometimes yielded unreliable results.

The new method called SalivaDirect is being further validated as a test for asymptomatic individuals through a programme that tests players and staff from the National Basketball Association (NBA).

SalivaDirect is simpler, less expensive and less invasive than the traditional method for such testing known as nasopharyngeal (NP) swabbing.

Results so far have found that SalivaDirect is highly sensitive and yields similar outcomes as NP swabbing.

With the FDA's emergency use authorisation, the testing method is immediately available to other diagnostic laboratories that want to start using the new test, which can be scaled up quickly for use across the nation and, perhaps, beyond in the coming weeks, researchers said.

A key component of SalivaDirect, the researchers note, is that the method has been validated with reagents and instruments from multiple vendors.

This flexibility enables continued testing if some vendors encounter supply chain issues as experienced early in the pandemic.

"This is a huge step forward to make testing more accessible," said Chantal Vogels, a Yale postdoctoral fellow, who led the laboratory development and validation along with Doug Brackney, an adjunct assistant clinical professor.

"This started off as an idea in our lab soon after we found saliva to be a promising sample type of the detection of SARS-CoV-2, and now it has the potential to be used on a large scale to help protect public health. We are delighted to make this contribution to the fight against coronavirus," he said.

Development of SalivaDirect as a means of rapidly expanding SARS-CoV-2 testing was spearheaded this spring by Nathan Grubaugh and Anne Wyllie, assistant professor and associate research scientist, respectively, at Yale School of Public Health. After finding saliva to be a promising sample type for SARS-CoV-2 detection, they wanted to improve the method further.

"With saliva being quick and easy to collect, we realised it could be a game-changer in COVID-19 diagnostics," said Wyllie.

With testing urgently needed, the Yale team was determined to decrease both testing times and costs, to make testing widely accessible.

"Wide-spread testing is critical for our control efforts. We simplified the test so that it only costs a couple of dollars for reagents and we expect that labs will only charge about USD 10 per sample. If cheap alternatives like SalivaDirect can be implemented across the country, we may finally get a handle on this pandemic, even before a vaccine," said Grubaugh.

Grubaugh and Wyllie said that they are not seeking to commercialise the method rather want the simplified testing method to help those most in need.

Testing for SARS-CoV-2 has been a major stumbling block in the fight against the pandemic, with long delays and shortages of testing.

Some experts have said that up to 4 million tests are needed per day and SalivaDirect provides one pathway toward that goal, the researchers said.

"Using SalivaDirect, our lab can double our testing capacity," said Professor Chen Liu, chair of Yale Pathology, who oversaw the clinical validation of the study.

Globally, coronavirus has infected 20,950,402 people while the disease has killed so far 760,213 others.

PTI

Tags : #USFDA #SalivaDirect #NewCovidTest #SalivabasedCovidTest #CheapestCovidTest #USFDapprovesSalivadirect #LatestPharmaNewsAug18 #LatestPharmaNewsUpdateAug18

About the Author


Team Medicircle

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

Digital Identity Fraud in Healthcare: What India Must KnowNovember 18, 2026
Wearables in Clinical Care: When Should Doctors Trust the Data?November 18, 2026
Cybersecurity for Medical Startups: What Founders MissNovember 18, 2026
Remote Patient Monitoring: The Next Phase of Virtual CareNovember 18, 2026
Digital Health Wallets: Future of Medical Records in IndiaNovember 17, 2026
How Hospitals Can Prepare for a Transparent Healthcare MarketNovember 17, 2026
Childhood Nutrition: Understanding Micronutrient Gaps Beyond CaloriesNovember 16, 2026
Anaemia in Adolescent Girls: Connecting Prevention, Testing and Nutrition SupportNovember 16, 2026
Health Information Exchanges in India: Are Medical Records Finally Going Portable?November 16, 2026
Hospital Accreditation in 2026: What Is Changing Beyond the Checklist?November 16, 2026
Digital Insurance Platforms and India's Health Coverage FutureNovember 14, 2026
ABDM 2.0: India's Digital Health Ecosystem FutureNovember 14, 2026
Vaccine Cold-Chain Management: Protecting Immunisation Quality From Storage to DeliveryNovember 14, 2026
Foodborne Illness Surveillance: How Public Health Systems Track RisksNovember 14, 2026
Interoperability in Indian Healthcare: Why Patient Data Still StrugglesNovember 13, 2026
Tuberculosis Contact Screening: How Preventive Care Works Around ExposureNovember 13, 2026
COPD Care in India: Linking Diagnosis, Inhaler Education and Follow-UpNovember 13, 2026
Management of ANCA Glomerulonephritis: Induction & Maintenance ProtocolsNovember 12, 2026
Smart Hospital Command Centres Transforming IndiaNovember 12, 2026
Gamma Knife Surgery in India: What You Need to KnowNovember 12, 2026